Preview Mode Links will not work in preview mode

Journal of Clinical Oncology recognizes that readers do not always have time to review an article in depth, and yet they still wish to understand how the results will influence their clinical practice or research. To address this need, we offer podcasts that will enhance the readership experience by presenting the key results of high-profile publications in a convenient audio format. Our podcasts are designed to place selected articles into a clinically useful perspective that is easy to listen to in the office or while on the road.

Life is busy, and it’s hard to get it all done during business hours! Journal of Clinical Oncology recognizes that you do not always have time to review an article in depth, and yet you wish to understand how the results will influence your clinical practice or research. JCO After Hours is a podcast intended to enhance the readership experience by presenting key results of high-profile publications in a convenient audio format, placing selected articles into a clinically useful perspective that you can listen to in the office or on the road.

Jan 30, 2012

This podcast summarizes and discusses the outcome results of the GOG Lap2 trial which shows safety and clinical benefits of laparoscopy as compared to laparotomy for surgical staging and treatment of uterine cancer.


Jan 30, 2012

This is a commentary on a report from the EBMT demonstrating a higher relapse rate after allogeneic transplantation in AML patients with FLT3 ITD mutations.


Jan 19, 2012

Long-term follow-up of efficacy and toxicity outcomes from the IES study of adjuvant aromatase inhibitor therapy in postmenopausal estrogen receptor positive breast cancer


Jan 9, 2012

This podcast discusses the findings from the manuscript by Munster et al. regarding the use of ovarian suppression for fertility preservation in young women receiving adjuvant chemotherapy in the context of the current literature and future directions.


Jan 9, 2012

The study by Marin et al is another milestone in our understanding how to manage CML patients on tyrosine kinase inhibitors.